L

ast July, Biogen (BIIB) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech’s maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience assets.

Biogen was eyeing prospective deals up to $10 billion to $12 billion in size, CEO Michel Vounatsos told investors.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.